Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
GRX Stock Summary
Top 10 Correlated ETFs
GRX
In the News
GRX: There Are Better Alternatives In The Healthcare CEF Sector
The Gabelli Healthcare & WellnessRx Trust is an underperforming equity closed-end fund (CEF) focused on healthcare stocks. GRX has a -19% discount to net asset value, but has traded at very substantial discounts for the past five years. The fund employs a 27% leverage ratio, which has hampered its performance in 2023.
GRX: Modest Healthcare Fund Trading At A Steep Discount
The Gabelli Healthcare & Wellness Rx Trust seeks to provide capital gains and income from a portfolio of healthcare and wellness-focused stocks. The fund pays an attractive 6.1% distribution yield that is well funded by its long-term 5-7% total returns. However, compared to peer funds, the GRX fund has much higher expenses, lower total returns, and higher portfolio volatility. I would personally seek healthcare exposure elsewhere.
The Month In Closed-End Funds: April 2023
For the first month in three, equity CEFs (+0.67% on a NAV basis) on average witnessed plus-side performance. While their fixed-income CEF cohorts (+0.56%) posted gains for the second consecutive month.
GRX: High-Yielding CEF Available At Discount, Suits Income-Seeking Investors
The Gabelli Healthcare & Wellness Rx Trust generates above-average yield and is available at a huge discount. However, its annual average total return over the past five years is not that high. Aging demographics and adoption of new medical products and services has started delivering long-term growth for healthcare firms for quite some time.
Weekly Closed-End Fund Roundup: VFL Tender Results (December 18, 2022)
2 out of 23 CEF sectors were positive on price and 2 out of 23 sectors were positive on NAV last week. VFL offers tender results.
GRX: Lagging Peers, But Discount Is Attractive
If you compare GRX to other healthcare peers, it has underperformed. However, GRX isn't focused solely on healthcare, so its portfolio has a bit more flexibility.
GRX: Steady Yield And Returns, Portfolio Looks Impressive After Restructuring
Between 2017 and 2021, GRX generated a yield of 5.2 percent and total return of 12 percent. It recorded positive returns in 8 out of the past 10 years. GRX's major investments generated mixed returns over the past 5 years. But the poor performing stocks have been replaced by well-performing ones.
GRX: Not Among The Best Closed-End Healthcare-Based Funds
GRX's total return has been negative, and yield has been quite average over the short term. GRX failed to record double digit average total return over the medium and long term.
GRX: Replicates The Market, But Fails To Beat
GRX's return has replicated the S&P 500 index, but has always performed less than the index.
The Month In Closed-End Funds: December 2021
The Month In Closed-End Funds: December 2021
GRX Financial details
GRX Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2023-12-31
Metric | History | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 3.15 | 1.6 | 2.52 | -2.74 | 0.98 | |
Net income per share | 3.12 | 1.55 | 2.48 | -2.78 | 0.03 | |
Operating cash flow per share | 0 | 2.89 | -1.1 | 3.41 | -0.02 | |
Free cash flow per share | 0 | 2.89 | -1.1 | 3.41 | -0.02 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 17.94 | 15.49 | 15.32 | 12.01 | 11.58 | |
Tangible book value per share | 17.98 | 18.09 | 15.32 | 12.01 | 11.58 | |
Share holders equity per share | 17.94 | 15.49 | 15.32 | 12.01 | 11.58 | |
Interest debt per share | 0 | 2.56 | 0.12 | 2.53 | 3.52 | |
Market cap | 196.33M | 186.85M | 233.86M | 175.15M | 148.87M | |
Enterprise value | 196.33M | 226.84M | 233.93M | 215.1M | 202.19M | |
P/E ratio | 3.69 | 7.73 | 5.47 | -3.69 | 352.11 | |
Price to sales ratio | 3.65 | 7.47 | 5.38 | -3.75 | 9.51 | |
POCF ratio | 0 | 4.13 | -12.35 | 3.01 | -417.62 | |
PFCF ratio | 0 | 4.13 | -12.35 | 3.01 | -417.62 | |
P/B Ratio | 0.64 | 0.77 | 0.89 | 0.86 | 0.81 | |
PTB ratio | 0.64 | 0.77 | 0.89 | 0.86 | 0.81 | |
EV to sales | 3.65 | 9.07 | 5.38 | -4.6 | 12.91 | |
Enterprise value over EBITDA | 3.69 | 9.38 | 5.47 | -4.86 | 63.1 | |
EV to operating cash flow | 0 | 5.01 | -12.35 | 3.7 | -567.19 | |
EV to free cash flow | 0 | 5.01 | -12.35 | 3.7 | -567.19 | |
Earnings yield | 0.27 | 0.13 | 0.18 | -0.27 | 0 | |
Free cash flow yield | 0 | 0.24 | -0.08 | 0.33 | 0 | |
Debt to equity | 0 | 0.17 | 0 | 0.2 | 0.29 | |
Debt to assets | 0 | 0.14 | 0 | 0.16 | 0.22 | |
Net debt to EBITDA | 0 | 1.65 | 0 | -0.9 | 16.64 | |
Current ratio | 0.66 | 1.4 | 0.08 | 1.89 | 0 | |
Interest coverage | 0 | 418.52 | 22.06 | -13.93 | 1.15 | |
Income quality | 0 | 2.1 | -0.44 | -1.22 | -0.84 | |
Dividend Yield | 0 | 0.06 | 0.07 | 0.09 | 0.07 | |
Payout ratio | 0 | 0.43 | 0.39 | -0.35 | 23.5 | |
Sales general and administrative to revenue | 0.01 | 0.03 | 0.02 | -0.02 | 0.04 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 35.48 | 23.21 | 29.23 | 27.43 | 2.63 | |
ROIC | 0.17 | 0.09 | 0.16 | -0.18 | 0.01 | |
Return on tangible assets | 0.17 | 0.08 | 0.12 | -0.19 | 0 | |
Graham Net | -0.02 | 0.01 | -5.02 | -2.29 | -3.36 | |
Working capital | -191.91K | 1.48M | -5.75M | 3.15M | -384 | |
Tangible asset value | 306.46M | 282.85M | 263.95M | 204.65M | 184.81M | |
Net current asset value | -191.91K | 1.48M | -86.41M | -37.37M | -54.23M | |
Invested capital | 0 | 0.17 | 0 | 0.2 | 0.29 | |
Average receivables | 387.96K | 2.74M | 2.79M | 3.55M | 3.7M | |
Average payables | 391.43K | 2.11M | 4.94M | 4.88M | 1.78M | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 2.57 | 74.58 | 3.99 | -51.78 | 18 | |
Days payables outstanding | 63.31 | 432.87 | 656.62 | 377.35 | 3.88 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 141.86 | 4.89 | 91.37 | -7.05 | 20.28 | |
Payables turnover | 5.77 | 0.84 | 0.56 | 0.97 | 94.1 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0.17 | 0.1 | 0.16 | -0.23 | 0 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-12-31 for Q4
Metric | History | 2021-12-31 | 2022-06-30 | 2022-12-31 | 2023-06-30 | 2023-12-31 |
---|---|---|---|---|---|---|
2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
Revenue per share | 0 | 0 | 0.47 | 0.17 | 0.81 | |
Net income per share | 0 | 0 | -0.04 | 0.29 | -0.27 | |
Operating cash flow per share | 0 | 0 | 0.11 | 0.04 | -0.06 | |
Free cash flow per share | 0 | 0 | 0.11 | 0.04 | -0.06 | |
Cash per share | 0 | 0 | 0 | 0 | 0 | |
Book value per share | 0 | 0 | 12.01 | 12.03 | 11.58 | |
Tangible book value per share | 0 | 0 | 12.01 | 15.9 | 11.58 | |
Share holders equity per share | 0 | 0 | 12.01 | 12.03 | 11.58 | |
Interest debt per share | 0 | 0 | 2.44 | 3.92 | 3.43 | |
Market cap | 0 | 0 | 175.15M | 166.13M | 148.87M | |
Enterprise value | 68.5K | -10.39K | 215.1M | 230.05M | 202.19M | |
P/E ratio | 0 | 0 | -59.88 | 8.66 | -8.51 | |
Price to sales ratio | 0 | 0 | 21.69 | 60.02 | 11.55 | |
POCF ratio | 0 | 0 | 96.27 | 248.52 | -145.25 | |
PFCF ratio | 0 | 0 | 96.27 | 248.52 | -145.25 | |
P/B Ratio | 0 | 0 | 0.86 | 0.83 | 0.81 | |
PTB ratio | 0 | 0 | 0.86 | 0.83 | 0.81 | |
EV to sales | 0 | 0 | 26.64 | 83.11 | 15.68 | |
Enterprise value over EBITDA | 0 | 0 | 255.41 | 37.3 | -68.23 | |
EV to operating cash flow | 0 | 0 | 118.23 | 344.13 | -197.27 | |
EV to free cash flow | 0 | 0 | 118.23 | 344.13 | -197.27 | |
Earnings yield | 0 | 0 | 0 | 0.03 | -0.03 | |
Free cash flow yield | 0 | 0 | 0.01 | 0 | -0.01 | |
Debt to equity | 0 | 0 | 0.2 | 0.32 | 0.29 | |
Debt to assets | 0 | 0 | 0.16 | 0.24 | 0.22 | |
Net debt to EBITDA | 0 | 0 | 47.44 | 10.36 | -17.99 | |
Current ratio | 0.08 | 11.65 | 1.89 | 34.61 | 0 | |
Interest coverage | 0 | 0 | 0.53 | 4.5 | -2.08 | |
Income quality | 0 | 0 | -2.49 | 0.14 | 0.23 | |
Dividend Yield | 0 | 0 | 0.06 | 0.03 | 0.03 | |
Payout ratio | 0 | 0 | -15.49 | 1.05 | -1.12 | |
Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
Graham number | 0 | 0 | 3.41 | 8.82 | 8.45 | |
ROIC | 0 | 0 | 0 | 0.02 | -0.01 | |
Return on tangible assets | 0 | 0 | 0 | 0.02 | -0.02 | |
Graham Net | 0 | 0 | -2.29 | 0.06 | -3.36 | |
Working capital | -5.75M | 473.5K | 3.15M | 1.33M | -384 | |
Tangible asset value | 263.95M | 211.06M | 204.65M | 265.25M | 184.81M | |
Net current asset value | -86.41M | -80.01M | -37.37M | 1.33M | -54.23M | |
Invested capital | 0 | 0 | 0.2 | 0.32 | 0.29 | |
Average receivables | 922.48K | 491.78K | 3.57M | 3.98M | 1.05M | |
Average payables | 3.25M | 3.14M | 1.79M | 1.78M | 35.68K | |
Average inventory | 0 | 0 | 0 | 0 | 0 | |
Days sales outstanding | 0 | 0 | 73.87 | 43.17 | 5.39 | |
Days payables outstanding | 0 | 0 | 196.63 | 2.33 | 1.95 | |
Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
Receivables turnover | 0 | 0 | 1.22 | 2.08 | 16.7 | |
Payables turnover | 0 | 0 | 0.46 | 38.66 | 46.11 | |
Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
ROE | 0 | 0 | 0 | 0.02 | -0.02 | |
Capex per share | 0 | 0 | 0 | 0 | 0 |
GRX Frequently Asked Questions
What is The Gabelli Healthcare & Wellness Trust stock symbol ?
The Gabelli Healthcare & Wellness Trust is a US stock , located in Rye of Ny and trading under the symbol GRX
What is The Gabelli Healthcare & Wellness Trust stock quote today ?
The Gabelli Healthcare & Wellness Trust stock price is $10.24 today.
Is The Gabelli Healthcare & Wellness Trust stock public?
Yes, The Gabelli Healthcare & Wellness Trust is a publicly traded company.